首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1222269篇
  免费   105654篇
  国内免费   27334篇
耳鼻咽喉   15569篇
儿科学   29362篇
妇产科学   29163篇
基础医学   163404篇
口腔科学   31364篇
临床医学   126932篇
内科学   212078篇
皮肤病学   20921篇
神经病学   87523篇
特种医学   48685篇
外国民族医学   395篇
外科学   167614篇
综合类   93910篇
现状与发展   89篇
一般理论   297篇
预防医学   93161篇
眼科学   30858篇
药学   104362篇
  429篇
中国医学   25823篇
肿瘤学   73318篇
  2022年   14210篇
  2021年   22940篇
  2020年   17372篇
  2019年   16709篇
  2018年   19208篇
  2017年   17236篇
  2016年   17043篇
  2015年   24245篇
  2014年   31660篇
  2013年   35453篇
  2012年   50486篇
  2011年   55112篇
  2010年   35024篇
  2009年   30272篇
  2008年   43443篇
  2007年   45192篇
  2006年   44156篇
  2005年   42987篇
  2004年   36038篇
  2003年   34773篇
  2002年   31673篇
  2001年   43713篇
  2000年   44171篇
  1999年   38786篇
  1998年   14277篇
  1997年   13481篇
  1996年   12345篇
  1995年   11661篇
  1994年   10800篇
  1992年   28885篇
  1991年   28040篇
  1990年   27235篇
  1989年   26080篇
  1988年   24377篇
  1987年   23888篇
  1986年   22576篇
  1985年   21684篇
  1984年   16710篇
  1983年   14238篇
  1979年   16859篇
  1978年   12179篇
  1977年   10231篇
  1976年   9360篇
  1975年   10174篇
  1974年   12674篇
  1973年   12164篇
  1972年   11574篇
  1971年   10704篇
  1970年   10239篇
  1969年   9928篇
排序方式: 共有10000条查询结果,搜索用时 693 毫秒
41.
通过病案举例,介绍大承气汤在中医脑病治疗中的使用技巧,说明大承气汤可以运用于出血性中风头痛、癫痫、失眠等多种脑病的治疗,疗效显著。大承气汤具有通腑泄热、祛邪外出的作用。对于六经辨证属阳明腑实证者,无论病种,皆可用大承气汤加味化裁。  相似文献   
42.
肿瘤免疫检查点抑制剂治疗为肿瘤患者带来生存获益的同时,也面临了许多挑战,例如免疫介导的肝毒性的发生。深入了解免疫检查点抑制剂治疗肿瘤过程中导致肝损伤的发生情况、可能机制、危险因素等,有助于更好地临床管理。  相似文献   
43.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
44.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
45.
46.
We report a Chinese family with members affected by epidermolytic ichthyosis (EI), caused by KRT gene mutations. The proband was a 14‐year‐old boy who had simultaneous appearance of nephroblastoma and epidermolytic ichthyosis (EI). Both the patient and his mother exhibited the specific clinical and pathological manifestations of EI. We analysed all exons and flanking sequences of the KRT1 and KRT10 genes using PCR, and found that the proband and his mother had a G>C transition at nucleotide position 1432 in exon 7 of KRT1, resulting in an amino acid substitution of glutamate (GAA) to glutamine (CAA) at codon 478 (E478Q). The KRT10 gene had no mutations.  相似文献   
47.
48.
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号